Pimavanserin
- Generic Name
- Pimavanserin
- Brand Names
- Nuplazid
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34FN3O2
- CAS Number
- 706779-91-1
- Unique Ingredient Identifier
- JZ963P0DIK
- Background
Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT and HT receptors. Unlike other atypical antipsychotics, pimavanserin lacks inherent dopaminergic activity. In fact, pim...
- Indication
用于伴随帕金森氏病精神病幻觉和妄想的治疗。
- Associated Conditions
- Delusions, Hallucinations
- Associated Therapies
- -
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT03118947
- Locations
- 🇺🇸
Miami Jewish Health Systems, Miami, Florida, United States
🇺🇸Acadia Hospital, Bangor, Maine, United States
🇨🇱Especialidades Medicas L y S, Santiago, Chile
Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
- Conditions
- Interventions
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT03018340
- Locations
- 🇺🇸
Carolina Clinical Trials, Inc., Charleston, South Carolina, United States
🇺🇸Woodland Research Northwest, Rogers, Arkansas, United States
🇺🇸Altea Research, Las Vegas, Nevada, United States
Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 396
- Registration Number
- NCT02970292
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 403
- Registration Number
- NCT02970305
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.